Form 4 for GILD Gilead Sciences
Accepted 2022-03-14 00:00:00 ET · period of report 2022-03-10 · accession 0001127602-22-009217 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-03-14 | 2022-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | M - OptEx | $0.00 | +24.0K | 260.4K | +10% | $0 |
| D | 2022-03-14 | 2022-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | F - Tax | $57.92 | -11.1K | 249.3K | -4% | -$640.1K |
| DM | 2022-03-14 | 2022-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | M - OptEx | — | -24.0K | 72.6K | -25% | — |
| DM | 2022-03-14 | 2022-03-10 | GILD | O'Day Daniel Patrick | COB, CEO, Dir | A - Grant | $0.00 | +464.0K | 137.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-10 | M | A | 10,800 | $0.00 | 247,193 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 2 | Common | Common Stock | 2022-03-10 | F | D | 11,052 | $57.92 | 249,344 | D | — | — | |
| 3 | Common | Common Stock | 2022-03-10 | M | A | 13,203 | $0.00 | 260,396 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 4 | Derivative | Restricted Stock Unit | 2022-03-10 | M | D | 10,800 | — | 85,772 | D | — · — to — | 10,800 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on each yearly anniversary of the date of grant until fully vested. |
| 5 | Derivative | Restricted Stock Unit | 2022-03-10 | M | D | 13,203 | — | 72,569 | D | — · — to — | 13,203 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 6 | Derivative | Non-qualified Stock Option (Right to Buy) | 2022-03-10 | A | A | 399,235 | $0.00 | 399,235 | D | $57.92 · — to 2032-03-10 | 399,235 Common Stock | (F4) The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 7 | Derivative | Restricted Stock Unit | 2022-03-10 | A | A | 64,745 | — | 137,314 | D | — · — to — | 64,745 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F3) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |